RESULTS OF A DOSE ESCALATION STUDY OF ME-401, A SELECTIVE PI3KΔ INHIBITOR, IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL)
		        
		        	EHA Library, John M Pagel, 
		        			                214903
		            		       
		    
				
			
		        A PHASE 1, PLACEBO-CONTROLLED STUDY TO DETERMINE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ESCALATING SUBCUTANEOUS DOSES OF LJPC-401 (SYNTHETIC HUMAN HEPCIDIN) IN HEALTHY ADULTS
		        
		        	EHA Library, Antonis Kattamis, 
		        			                214932
		            		       
		    
				
			
		        LONG TERM INTEGRATED SAFETY ANALYSIS OF UMBRALISIB (TGR-1202), A PI3K-DELTA/CK1-EPSILON INHIBITOR WITH A DIFFERENTIATED SAFETY PROFILE, IN PATIENTS WITH RELAPSED/REFRACTORY LYMPHOID MALIGNANCIES
		        
		        	EHA Library, Matthew S. Davids, MD, MMSC, 
		        			                214906
		            		       
		    
				
			
		        AN OPEN-LABEL, MULTICENTER, SINGLE-ARM, PHASE II STUDY ASSESSING PATIENT PREFERENCE FOR THE DEFERASIROX FILM-COATED TABLET COMPARED TO THE REFERENCE DISPERSIBLE TABLET FORMULATION: THE JUPITER STUDY
		        
		        	EHA Library, Vip Viprakasit, 
		        			                214937